Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
Travel sourcing and consultancy group Partnership Travel Consulting has named former Corporate Travel Management executive Maureen Brady as its chief commercial officer, a new position for the group.
The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...
Multibagger Stock: PTC Industries, an engineering component manufacturer, has experienced a remarkable surge in its share ...
Netflix is planning a busy end of the year with already a few debuts that haven’t dropped yet for the end of November and a ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
GlobalData on MSN12h
FDA grants accelerated approval for PTC’s AADC deficiency gene therapyThis therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) ...
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback